An interventional study of Proton Pump Inhibitor deprescribing tool in Inappropriate Prescribing, Reflux Disease and Proton Pump Inhibitors, sponsored by University of Bern. Recruiting at 2 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by University of Bern · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Gastroesophageal Reflux with a site in Switzerland — 13 open to participants now, 14 under way, none of them phase 3. Gastroesophageal Reflux · Switzerland.
Among the 31 studies in Gastroesophageal Reflux with a site in Switzerland, this one is the 3rd largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2024, is one of 9 with no phase, reaches primary completion later than 7 of the 13 other live ones, and was the 26th registered.
1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.
Browse Gastroesophageal Reflux studies →13 of the 31 studies in Gastroesophageal Reflux with a site in Switzerland are open now. Recruiting first, the newest first:
University Hospital, Geneva · Sites in Switzerland
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+
Prof Urs Zingg · Sites in Switzerland
Ages 18+
Implantica CE Reflux Ltd. · Sites in Switzerland, Germany, Italy and 1 more country
Ages 18+
Medtronic Cardiovascular · Sites in Switzerland, Denmark, France and 5 more countries
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 4 · Phase 4 3
First in 2003; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 68 across 800 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 67 across the 20 interventional studies, 350 across the 10 observational. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 31 have an industry lead sponsor. The 10 most frequent:
University of Bern is the lead sponsor of 209 studies on the registry; 46 are open to participants now.
University of Bern has 1 study filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
3 of the studies in Gastroesophageal Reflux with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07004400Implantica CE Reflux Ltd.A Blinded Randomized Clinical Study of RefluxStop™ Compared With Nissen Fundoplication in the Treatment of GERD | 2026-12-01 |
| NCT07506356University Hospital, GenevaInvestigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors | 2026-12-31 |
| NCT06129474University of BernDeprescribing Inappropriate Proton Pump Inhibitors | 2027-04-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies in Gastroesophageal Reflux with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The DROPIT Trial is an interventional, open-labelled, cluster-randomized controlled trial conducted in the Swiss primary care setting. It aims to evaluate an intervention to guide the deprescribing of inappropriate proton-pump inhibitors (PPIs). Therefore, the trial investigates whether the study intervention leads to the deprescribing of inappropriate PPI prescription while ensuring noninferiority safety, in comparison to usual care. Additionally, the trail aims to investigate the intervention's impact on other clinical aspects, as well as addressing features of the implementation of the intervention and its cost-effectiveness.
Background and rational:
Proton pump inhibitors (PPIs) are the most frequent treatment of gastric acid related disorders. The use of PPIs is increasing, as well as concerns about their inappropriate use. Long-term use of PPIs has been associated with adverse events (e.g., nutritional deficiencies, osteoporosis, infections). Therefore, deprescribing (stopping or reducing dose) PPIs when they are not or no longer indicated is expected to benefit the patients. While general practitioners (GPs) and patients may be reluctant to deprescribing, studies suggest that clinicians would be more comfortable with deprescribing after additional training, and that patients' acceptance increases following recommendations from their doctor. This highlights the importance of providing GPs and patients with the necessary tools for safe deprescribing. In Switzerland, there is evidence of PPI use without adequate indication or dose.
In the pilot survey conducted within the current project, which involved 48 GPs, 55% of them reported often encountering patients who were prescribed inappropriate PPIs, and 58% expressed a desire for a PPI deprescribing guideline. Optimizing PPI use in Switzerland is needed and of interest. Therefore, the investigators aim to conduct a clinical trial to evaluate an intervention to guide deprescribing of inappropriate PPIs. Additionally, alongside the trial, there will be an integrated process evaluation of the intervention, and a cost-effectiveness evaluation.
Study design:
This interventional, open-labelled, cluster-randomized controlled trial in Swiss primary care setting, aims to evaluate an intervention to guide deprescribing of inappropriate PPIs. In this trial, adult patients with inappropriate PPI prescription will be recruited by GPs in the German speaking part of Switzerland. Based on 1:1 cluster randomization of GPs, patients will be assigned to either the control group or to the group receiving an intervention to guide deprescribing of inappropriate PPIs. The control group will receive usual care. The investigators will compare the effectiveness and safety of the intervention with usual care, over a 12-month follow-up period. Alongside the trial, an integrated process evaluation of the intervention and a cost-effectiveness evaluation will be conducted.
Objectives:
The main goal of this study is to evaluate an intervention to guide deprescribing of inappropriate PPIs. Therefore, the main trial aims to investigate if the study intervention leads to the deprescribing of inappropriate PPI prescription (i.e., effectiveness of the intervention), while ensuring noninferiority safety, in comparison to usual care. Additionally, the trial aims to investigate its impact on other clinical aspects, like the number of medications used, the health-related quality of life, and additional safety endpoints.
Alongside the main trial, an integrated process evaluation of the intervention aims to evaluate the quality of the implementation, as well as GPs' and patients' acceptance and fidelity to the intervention, patient typology, and the mechanisms supporting or hindering the success of the intervention.
Also, alongside the main trial, a cost-effectiveness evaluation aims to investigate the cost implications of the
Statistical considerations:
Statistical methods for the main trial The prescribed PPI dose will be quantified using the defined daily dose (DDD). To quantify its change the investigators will 1) estimate the average PPI dose over the 12 months of follow-up using the area under the curve divided by the time under observation and, 2) calculate the relative change from baseline as one minus the ratio between the average prescription and the baseline prescription level. The difference in the change in prescribed PPI dose between the two groups will be calculated using a linear model, adjusted for the baseline dose and including a random effect for the cluster. The difference in the change in upper gastrointestinal symptoms between the two groups will be calculated from a repeated-measures linear mixed-effects model, adjusted for the baseline value and including the intervention group, the timepoint, and the interaction between group and timepoint as fixed effects. Effects of the cluster and patient will be added as random effects. Both intention-to-treat (ITT) and per-protocol analyses need to meet non-inferiority to claim success for the co-primary safety endpoint.
Statistical analyses for other endpoints Repeatedly measured continuous secondary endpoints will be analyzed using the same model as for the safety co-primary endpoint. Count endpoints will be analyzed using a generalized linear mixed model and a negative binomial distribution, including the random effect of the cluster and the time of observation as an offset. Binary endpoints assessed at the end of the follow-up period will be analysed using mixed effects logistic regression, adjusted for the time under observation and including the random effect of the cluster.
Statistical methods for the integrated process evaluation of the intervention The process evaluation will be done based on the Medical Research Council's evaluation framework for complex interventions. Adherence to deprescribing decisions will be investigated using temporal dynamics modelling. Mechanisms of impact will be investigated based on the health action process approach, an established health behaviour change theory. The qualitative part will consist of semi-structured in-depth interviews with both patients and GPs.
Statistical methods for the cost-effectiveness evaluation Health economic analysis will be performed from a Swiss statutory health insurance perspective with a primary time horizon. QALYs will be estimated as the area under the survival curve resulting from utility estimates obtained for the different assessment timepoints during the trial. Utilities will be derived from EQ- 5D-5L questionnaire responses based on published valuation algorithms. A regression-based approach to assess intervention effects will be adopted due to the clustered nature of the trial data and possibility of residual baseline imbalances. The investigators will use Generalized Structural Equation Models (GSEMs), which will allow to simultaneously estimate incremental costs and QALYs (i.e., the intervention effects on costs and QALYs in the regression models), while accounting for the clustered nature of the data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
PPI in one of the following doses:
Exclusion Criteria:
PPI in an appropriate dose (see Appendix Table A1) and with an established indication for long-term PPI, such as:
Medications (any dose):
Risk factors:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study intervention is a patient-centred PPI deprescribing intervention aiming to guide GPs and patients through the process of safely deprescribing inappropriate PPIs.
Other: Proton Pump Inhibitor deprescribing tool
The reference or control arm will receive usual care. This means that the GPs and patients in this group will conduct their clinical practice as per usual, without receiving the intervention from the study team.
The intervention is targeted to the Swiss Primary care practice. It involves educational material and resources to guide the safe deprescribing of inappropriate PPIs, for both general practitioners and patients.
Effectiveness co-primary endpoint: prescribed PPI dose over 12 months follow-up (superiority endpoint).
Time frame: 12 months
Safety co-primary endpoint: upper gastrointestinal symptoms (Non-inferiority endpoint)
Co-primary endpoints measured by the Reflux Disease Questionnaire (RDQ), considering the worst of the subscales dyspepsia and gastroesophageal reflux disease (GERD) (i.e.,regurgitation and heartburn subscales combined).
Time frame: 12 months
Occurrence of reduction of at least 50% of the prescribed PPI dose over the follow-up time.
Time frame: 12 months
Occurrence of PPI discontinuation
Stop in PPI prescription as indicated by the general practitioner (GP)
Time frame: 12 months
Occurrence of PPI sustained discontinuation
3 months without prescribed PPI
Time frame: 12 months
Occurrence of a switch to prescription for on-demand use
Time frame: 12 months
Occurrence of use of alternative anti-reflux treatments
i.e., alginate-based compounds, anti-acids, H2-blockers
Time frame: 12 months
Regurgitation
Measured with the Reflux Disease Questionnaire (RDQ). The RDQ score ranges from 0 (not present) to 5 (severe) per symptom.
Time frame: 12 months
Heartburn
Measured with the Reflux Disease Questionnaire (RDQ). The RDQ score ranges from 0 (not present) to 5 (severe) per symptom.
Time frame: 12 months
Dyspepsia
Measured with the Reflux Disease Questionnaire (RDQ). The RDQ score ranges from 0 (not present) to 5 (severe) per symptom.
Time frame: 12 months
Atypical gastrointestinal symptoms
Symptoms measured by the Reflux Symptom Index (RSI). The RSI scales for each individual item ranges from 0 (no problem) to 5 (severe problem), with a maximum total score of 45.
Time frame: 12 months
Occurrence of ulcers and/or gastrointestinal bleeding
Time frame: 12 months
Occurrence of potential side effects of PPI overuse during the conduct of the trial.
Potential side effects include vitamin B12, iron (Fe), magnesium (Mg), and sodium (Na) deficiencies, osteoporosis, small intestinal bacterial overgrowth (SIBO), anemia, fractures, nephritis, and intestinal infections (C.diff., enteritis-salmonella, campylobacter).
Time frame: 12 months
Quality of life (EQ-5D-5L)
Assessed by the European Quality of Life 5-Dimensions 5-Levels (EQ-5D-5L) questionnaire. The VAS score from this questionnaire will be analyzed in the main DROPIT paper, all other questions and the resulting score will be analyzed in the health economic paper conducted alongside the trial.
Time frame: 12 months
Number of all medications prescribed during the conduct of the trial
Measured using the Anatomical Therapeutic Chemical (ATC) code
Time frame: 12 months
Serious adverse events (SAE)
A Serious Adverse Event (SAE) (ClinO, Art. 63) is any untoward medical occurrence that results in death or is life-threatening, requires in-patient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or causes a congenital anomaly or birth defect. Upon a SAE, the GP makes the severity assessment of the event following the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.
Time frame: 12 months
Mortality
Time frame: 12 months
Patients' satisfaction with the trial participation
Measured by the Study Participant Feedback Questionnaire (SPFQ), handed to at the beginning (baseline), middle (6-month) and end of trial (12-month).
Time frame: 12 months
Use of alternative anti-reflux treatments (medication)
After PPI discontinuation and after PPI sustained discontinuation
Time frame: 12 months
New PPI prescription
Addressed after PPI discontinuation and after PPI sustained discontinuation
Time frame: 12 months
Plan to share: Yes — Following informed consent for data sharing, data could be shared upon request to the sponsor-investigator. The data is owned by the sponsor-investigators. In case of data sharing, a data sharing agreement between the external party and the sponsor-investigator will need to be agreed on and signed.
Started Oct 2024 (actual). Primary completion is estimated for Apr 2027, 30 months after the start.
Of 194 non-industry interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 68. This study's planned 30 months is close to that.
Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.